Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Invested Capital (2016 - 2025)

Haemonetics has reported Invested Capital over the past 16 years, most recently at $2.1 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 77.28% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $2.1 billion, up 77.28%, while the annual FY2025 figure was $2.0 billion, 67.41% up from the prior year.
  • Invested Capital for Q4 2025 was $2.1 billion at Haemonetics, up from $2.1 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $2.1 billion in Q4 2025 and troughed at $677.1 million in Q3 2021.
  • A 5-year average of $1.3 billion and a median of $1.2 billion in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: skyrocketed 93.85% in 2021 and later plummeted 33.97% in 2023.
  • Year by year, Invested Capital stood at $991.6 million in 2021, then increased by 6.13% to $1.1 billion in 2022, then decreased by 10.37% to $943.3 million in 2023, then rose by 27.74% to $1.2 billion in 2024, then soared by 77.28% to $2.1 billion in 2025.
  • Business Quant data shows Invested Capital for HAE at $2.1 billion in Q4 2025, $2.1 billion in Q3 2025, and $2.1 billion in Q2 2025.